

Contents

| Title | Content | Pg.No. |
|--------------------|--|----------|
| | Declaration by Research Scholar–Originality of Research Work | I |
| | Certificate of Supervisor | II |
| | Thesis Approval Form | III |
| | Declaration by Research Scholar – Submission of Thesis | IV |
| | Acknowledgement | V |
| | Contents | VII |
| | List of Figures | XI |
| | List of Tables | XV |
| | Abstract | XVIII |
| | Abbreviations | XXI |
| Chapter : 1 | Introduction | 1 |
| | 1.1 Oral Route of Drug Administration | 1 |
| | 1.2 Lipid Formulation Classification System | 2 |
| | 1.3 Self-Emulsifying Drug Delivery Systems | 3 |
| | 1.4 Mechanism of Self-emulsification | 4 |
| | 1.5 Composition of SNEDDS | 6 |
| | 1.5.1 Active Pharmaceutical Ingredient (API) | 6 |
| | 1.5.2 Oil | 7 |
| | 1.5.3 Surfactant | 8 |
| | 1.5.4 Co-surfactant | 9 |
| | 1.5.5 Antioxidants | 10 |
| | 1.5.6 Polymers | 10 |
| | 1.6 Approaches for preparation of Nanoemulsion | 11 |
| | 1.6.1. High-energy approach | 11 |
| | 1.6.2. Low-energy approach | 13 |
| | 1.7 Steps for the Design of SNEDDS | 14 |
| | 1.7.1 Selection of Drugs | 15 |
| | 1.7.2 Screening of a mixture of excipients | 15 |
| | 1.7.3 Construction of Ternary Phase Diagrams | 16 |
| | 1.7.4 Solid SNEDDS | 17 |
| | 1.7.6 Characterization of SNEDDS | 19 |

| | |
|--|-----------|
| 1.8 Potential of SNEDDS in Bioavailability Enhancement | 25 |
| 1.9 Advantages of SNEDDS | 26 |
| 1.10 Limitations of SNEDDS | 27 |
| 1.11 Challenges in Formulations | 28 |
| 1.12 Patent on Self-Nanoemulsifying Drug Delivery Systems | 29 |
| 1.13 Application of Quality by Design (QBD) in Formulation | 30 |
| 1.13.1 Terminology Utilized in Optimization | 32 |
| 1.13.2 Types of Designs | 33 |
| 1.14 Current status of Hypertension in the world | 36 |
| 1.15 Combination therapy for Hypertension treatment | 38 |
| 1.16 SNEDDS applied for Enhancement of Bioavailability of Anti-Hypertensive Drugs | 39 |
| 1.17 Need and Objective of the work | 41 |
| 1.18 Plan of work | 44 |
| Chapter : 2 Literature Review | 46 |
| 2.1 Review of Work done on Benidipine | 46 |
| 2.2 Review of Work done on Telmisartan | 50 |
| 2.3 Review of work done on combination of Benidipine with Telmisartan | 55 |
| 2.4 Review of work done on preparation of Self Emulsifying Drug delivery system | 57 |
| 2.5 Review of work done on preparation of Self Emulsifying Drug delivery system using QBD Approach | 65 |
| 2.6. Review of work done on Pharmacology study | 70 |
| Chapter : 3 Materials and Methods | 74 |
| 3.1 Materials | 74 |
| 3.1.1 Drug profile | 75 |
| 3.1.2 Excipients profile | 82 |
| 3.1.3. Equipment & Software | 117 |
| 3.2 Methods | 118 |
| 3.2.1 Characterization of Benidipine (BD) and Telmisartan (TEL) | 118 |

| | |
|---|------------|
| 3.2.2 Analytical method development and validation for estimation of BD and BD with TEL | 120 |
| 3.2.3. Compatibility studies | 121 |
| 3.2.4. Application of Quality by Design (QbD) | 122 |
| 3.2.5A Formulation and development of benidipine SNEDDS | 123 |
| 3.2.5B Formulation and development of benidipine with telmisartan SNEDDS | 129 |
| 3.2.6. Characterization of L-SNEDDS Formulations of BD and BD with TEL | 134 |
| 3.2.7. Evaluation of Optimized Formulation of L-SNEDDS of BD and BD with TEL | 136 |
| 3.2.8. Preparation of S- SNEDDS | 137 |
| 3.2.9. Characterization of S-SNEDDS of BD and BD with TEL | 138 |
| 3.2.10.Optimization of S-SNEDDS of BD and BD with TEL | 140 |
| 3.2.11 Pharmacodynamics Research of Benidipine and Benidipine with Telmisartan | 141 |
| 3.12. Accelerated Stability Research | 143 |
| Chapter : 4 Results and Discussion | 144 |
| 4.1. Characterization of BD and TEL | 144 |
| 4.1.1 Physicochemical characterization | 144 |
| 4.1.2 Identification test using spectrum analysis of BD and TEL | 144 |
| 4.1.3 Analytical technique development and validation for the determination of BD and TEL | 147 |
| 4.1.4 Compatibility studies | 150 |
| 4.2 QbD approach | 152 |
| 4.2.1 QTPP (Quality target product profile) | 152 |
| 4.2.2. CQAs (Critical quality attributes) | 152 |
| 4.2.3. Risk Evaluation | 153 |
| 4.3. Formulation and development of SNEDDS | 156 |
| 4.3A Formulation and development of benidipine SNEDDS | 156 |
| 4.3B Formulation and development of benidipine with telmisartan SNEDDS | 174 |

| | |
|---|------------|
| 4.4. Assessment of Drug-loaded Optimum Formulation | 192 |
| 4.4A. Assessment of BD-Loaded Optimum Formulation | 192 |
| 4.4B Assessment of BD with TEL-Loaded Optimum Formulation | 200 |
| 4.5 Preparation of S- SNEDDS | 208 |
| 4.5.1 Characterization of S-SNEDDS of BD and BD with TEL | 211 |
| 4.6. Pharmacodynamics Research of Benidipine and Benidipine with Telmisartan | 220 |
| 4.7 Accelerated stability study | 224 |
| Bibliography | 226 |
| Appendix A Plagiarism Report | 246 |
| Appendix B Publication | 248 |
| Appendix C Summary | 256 |

List of Figures

| Figure No. | Name of Figure | Pg.No. |
|----------------------|--|---------------|
| Figure 1.1 | Process of Self Emulsification | 5 |
| Figure 1.2 | Mechanism of self-nano emulsifying drug delivery systems (SNEDDS) | 10 |
| Figure 1.3 | Typical ternary phase diagram of oil, surfactant and water system | 17 |
| Figure 1.4 | Overview of potential mechanism of SNEDDS to enhance bioavailability of drugs | 26 |
| Figure 1.5 | Different types of CCD | 35 |
| Figure 1.6 | Three-factor Box-Behnken design | 36 |
| Figure 3.1 | Chemical structure of Benidipine | 75 |
| Figure 3.2 | Chemical structure of Telmisartan | 79 |
| Figure 4.1 | UV spectroscopy of BD and TEL | 145 |
| Figure 4.2(a) | FTIR spectra of BD | 145 |
| Figure 4.2(b) | FTIR spectra of TEL | 146 |
| Figure 4.3 | DSC spectrum of BD and TEL | 147 |
| Figure 4.4 | Standard calibrations Curve of BD in methanol and 0.1N HCl | 149 |
| Figure 4.5 | Overlain spectra of BD (5 µg/ml) and TEL (50 µg/ml) | 149 |
| Figure 4.6 | DSC spectrum of mixture of BD and TEL. | 151 |
| Figure 4.7 | FTIR spectrum of mixture of BD and TEL | 152 |
| Figure 4.8 | Ishikawa Fishbone diagram portraying causes and sub causes influencing S-SNEDDS of BD and BD with TEL quality attributes | 153 |
| Figure 4.9 | A)Solubility of BD in various oil, b) solubility of BD in different surfactants and c) solubility of BD in different co-surfactants | 160 |
| Figure 4.10 | Ternary phase diagrams of the o/w emulsified regions of 1:1, 2:1, and 3:1 ratios of Labrafil M 2125 CS, Kolliphor EL, and Transcutol P | 161 |
| Figure 4.11 | 2D contour plot response for emulsification time of BD SNEDDS | 169 |
| Figure 4.12 | 2D contour plot response for droplet size of BD SNEDDS | 169 |

| | | |
|--------------------|--|-----|
| Figure 4.13 | 2D contour plot response for drug release at 15 min of BD SNEDDS | 170 |
| Figure 4.14 | 2D contour plot response for %transmittance of BD SNEDDS | 170 |
| Figure 4.15 | Response surface plots for emulsification time of BD SNEDDS | 171 |
| Figure 4.16 | Response surface plots for droplet size of BD SNEDDS | 171 |
| Figure 4.17 | Response surface plots for drug release at 15 min of BD SNEDDS | 172 |
| Figure 4.18 | Response surface plots for %transmittance of BD SNEDDS | 172 |
| Figure 4.19 | Overlay plot for optimized formulation of BD-loaded-SNEDDS | 173 |
| Figure 4.20 | Bar chart defining the Benidipine with Telmisartan solubility in different oils, surfactants and co-surfactants | 177 |
| Figure 4.21 | Ternary phase diagrams of the o/w emulsified regions of 1:1, 2:1, 3:1, 1:3 and 1:2 ratios of Eucalyptus oil, Kolliphor EL, and Transcutol P. | 179 |
| Figure 4.22 | 2D contour plot response for self-emulsification time of BD with TEL-SNEDDS | 186 |
| Figure 4.23 | 2D contour plot response for droplet size of BD with TEL SNEDDS. | 186 |
| Figure 4.24 | 2D contour plot response for % of BD release in 15 minutes of BD with TEL-SNEDDS | 187 |
| Figure 4.25 | 2D contour plot response for % of TEL release in 15 minutes of BD with TEL-SNEDDS | 187 |
| Figure 4.26 | 2D contour plot response for % transmittance of BD with TEL-SNEDDS | 188 |
| Figure 4.27 | Response surface plots for emulsification time of BD with TEL-SNEDDS | 188 |
| Figure 4.28 | Response surface plots for droplet size of BD with TEL-SNEDDS | 189 |
| Figure 4.29 | Response surface plots for % of BD release in 15 minutes of BD with TEL-SNEDDS | 189 |
| Figure 4.30 | Response surface plots for % TEL release in 15 minutes of BD with TEL-SNEDDS | 190 |
| Figure 4.31 | Response surface plots for % transmittance of BD with TEL-SNEDDS | 190 |

| | | |
|--------------------|--|-----|
| Figure 4.32 | Overlay plot for optimized formulation of BD with TEL-loaded-SNEDDS | 191 |
| Figure 4.33 | Effect of dilution on droplet size and zeta potential | 193 |
| Figure 4.34 | A) Droplet size distribution by intensity B) Zeta potential assessment of the augmented SNEDDS BD14 loaded with benidipine | 195 |
| Figure 4.35 | TEM images of the optimized benidipine SNEDDS - BD14 | 197 |
| Figure 4.36 | In-vitro drug released study of pure Benidipine and developed SNEDDS batches of Benidipine | 199 |
| Figure 4.37 | Comparative in vitro drug release studies of BD aqueous suspension, BD-L-SNEDDS, and BD marketed product | 200 |
| Figure 4.38 | Effect of Dilution on Droplet size and Zeta potential in S-SNEDDS of BT11 | 201 |
| Figure 4.39 | Zeta potential of optimized liquid SNEDDS of Benidipine with Telmisartan BT11 | 203 |
| Figure 4.40 | TEM images of the optimized BD with TEL-loaded SNEDDS | 206 |
| Figure 4.41 | In-vitro drug released study of pure Benidipine and Telmisartan and developed SNEDDS batches of Benidipine with Telmisartan | 207 |
| Figure 4.42 | Comparative in vitro drug release studies of Benidipine with Telmisartan pure drug, Benidipine with Telmisartan liquid SNEDDS, BT11, and Market formulation (Benidip T 4 mg/40 mg Tab) | 208 |
| Figure 4.43 | FTIR spectra of (A) Neusilin US2, (B) physical mixture of BD and Neusilin US2, (C) BD, and (D) S-SNEDDS BD14 | 212 |
| Figure 4.44 | DSC Thermogram of (a) Neusilin US2, (b) BD, and (c) optimized S-SNEDDS BD14 | 213 |
| Figure 4.45 | SEM image of (A) Pure drug and BD (B) S-SNEDDS of BD14. | 213 |
| Figure 4.46 | XRD patterns of (A) BD, (B) Neusilin US2, and (C) S-SNEDDS BD14 | 214 |
| Figure 4.47 | Comparative in vitro drug release studies of BD aqueous suspension, BD-L-SNEDDS, BD14-S-SNEDDS, and BD marketed product | 215 |

| | | |
|--------------------|--|-----|
| Figure 4.48 | FTIR spectra of (A) Neusilin US2, (B) Physical mixture of Benidipine, Telmisartan and Neusilin US2, (C) Benidipine with Telmisartan and (D) S-SNEDDS of Benidipine with Telmisartan | 216 |
| Figure 4.49 | DSC Thermogram of (a) Neusilin US2, (b) Benidipine with Telmisartan and (c) Optimized S-SNEDDS of Benidipine with Telmisartan | 217 |
| Figure 4.50 | SEM image of (A) Pure drug Benidipine with Telmisartan (B) S-SNEDDS of BT11 | 217 |
| Figure 4.51 | PXRD of (A) Drug: Benidipine with Telmisartan (B) Neusilin US2, (C)S-SNEDDS of BD with TEL | 218 |
| Figure 4.52 | Comparative in vitro drug release studies of pure Benidipine, Telmisartan, Benidipine with Telmisartan liquid SNEDDS, BT11, S-SNEDDS of BT11 and Market formulation (Benidip T 4 mg/40 mg Tab) | 219 |
| Figure 4.53 | Instrumental setup for measurement of Systolic blood pressure, Mean Arterial pressure and Diastolic blood pressure | 220 |
| Figure 4.54 | Systolic blood pressure, Mean Arterial pressure and Diastolic blood pressure values before and after benidipine treatment to different group (n=6rats/group) | 223 |
| Figure 4.55 | Systolic blood pressure, Mean Arterial pressure and Diastolic blood pressure values before and after benidipine with telmisartan treatment to different group (n=6rats/group) | 223 |

List of Tables

| Table No. | Name of Table | Pg. No. |
|-------------------|---|----------------|
| Table 1.1 | Major distinctions among SEDDS, SMEDDS and SNEDDS | 4 |
| Table 1.2 | Marketed products founded on SNEDDS | 4 |
| Table 1.3 | Assessment of the in vitro performance of the formulations | 21 |
| Table 1.4 | Patent on SNEDDS | 30 |
| Table 1.5 | Factor and level for optimization | 32 |
| Table 1.6 | Different experimental designs applied for optimization | 34 |
| Table 1.7 | Different designs with different number of levels with accuracy of estimates. | 35 |
| Table 1.8 | Potential of SNEDDS for Enhancement of Bioavailability of Anti-Hypertensive Drugs | 41 |
| Table 3.1 | Marketed formulations of Benidipine | 78 |
| Table 3.2 | Marketed formulations of Telmisartan | 81 |
| Table 3.3 | List of chemicals used for experimental work | 82 |
| Table 3.4 | Typical Application and Quantity Required for Neusilin® US2 | 117 |
| Table 3.5 | List of Equipment's used | 118 |
| Table 3.6 | List of software | 118 |
| Table 3.7 | Three-factor CCD experiment design grid with variable for SNEDDS of BD | 126 |
| Table 3.8 | Variables in CCD for SNEDDS of BD | 126 |
| Table 3.9 | Coded value and converted value for the proposed matrix according to the CCD design batches | 128 |
| Table 3.10 | Three-factor BBD experiment design grid with variable for SNEDDS of BD with TEL | 132 |
| Table 3.11 | Three-factor BBD experiment design grid with variable for SNEDDS of BD with TEL | 133 |
| Table 3.12 | Design plan of Box-Behnken Design batches for the prepared SNEDDS of BD with TEL | 134 |
| Table 3.13 | Study design for Pharmacodynamics study | 142 |
| Table 4.1 | Physicochemical characterization of BD and TEL | 144 |
| Table 4.2 | Reported and obtained value of λ_{max} for BD and TEL | 145 |
| Table 4.3 | FTIR bands with characteristic functional group of BD and TEL | 146 |

| | | |
|-------------------|--|-----|
| Table 4.4 | Data of standard calibration curve of BD in methanol at 237 λ_{\max} | 148 |
| Table 4.5 | Data of standard calibration curve of BD in 0.1N HCl at 237 λ_{\max} | 148 |
| Table 4.6 | Linear regression analysis for calibration curve of BD | 148 |
| Table 4.7 | Data indicating recovery studies of BD and TEL | 150 |
| Table 4.8 | Data indicating recovery studies of BD and TEL | 150 |
| Table 4.9 | Quality Target Product Profile (QTPP) of Benidipine S-SNEDDS and Benidipine with Telmisartan S-SNEDDS | 154 |
| Table 4.10 | Critical quality attributes (CQAs) for S-SNEDDS of BD and BD with TEL and their justifications | 155 |
| Table 4.11 | Solubility of Benidipine in various oil | 157 |
| Table 4.12 | Solubility of Benidipine in various Surfactant | 158 |
| Table 4.13 | Selection of Co-surfactant on the basis of solubility and % T | 159 |
| Table 4.14 | An overview of the CQAs observed for formulations of BD created by the CCD design | 163 |
| Table 4.15 | Regression analysis of the CCD categories of BD-loaded SNEDDS | 164 |
| Table 4.16 | Outcomes of the ANOVA test for the BD-loaded SNEDDS | 166 |
| Table 4.17 | Predicted and measured values for optimized BD-loaded SNEDD | 173 |
| Table 4.18 | Solubility of Benidipine with Telmisartan in various Oil | 175 |
| Table 4.19 | Emulsification study of Eucalyptus oil for the surfactant and cosurfactant selection of Benidipine and Telmisartan | 176 |
| Table 4.20 | An overview of the CQAs observed for formulations of BD with TEL created by the BBD design | 180 |
| Table 4.21 | Regression assessment of BD with TEL loaded SNEDDS created by the BBD design | 181 |
| Table 4.22 | Outcomes of the ANOVA test for the BD-loaded SNEDDS | 183 |
| Table 4.23 | Overlay plot for optimized formulation of BD with TEL-loaded-SNEDDS | 192 |
| Table 4.24 | Evaluation of SNEDDS BD1 to BD15 formulation of design | 194 |
| Table 4.25 | Thermodynamic stability investigations of various Benidipine SNEDDS formulations | 196 |
| Table 4.26 | Comparison of dissolution profile of various SNEDDS of benidipine formulation with pure drug | 199 |
| Table 4.27 | Evaluation of L-SNEDDS BT1 to BT15 Formulation of design | 202 |